Related Experiment Videos
Melanotic neuroectodermal tumor of infancy and fetal hydantoin syndrome
Insights
Fetal hydantoin syndrome (FHS) in children exposed to hydantoin anticonvulsants may be linked to cancer. This study reports a rare tumor in an FHS patient, suggesting a potential oncogenic effect of these medications.
Area of Science:
- Teratology
- Oncology
- Developmental Pediatrics
Background:
- Fetal hydantoin syndrome (FHS) is associated with maternal use of hydantoin anticonvulsants during pregnancy.
- Previous reports suggest a potential oncogenic effect of hydantoin compounds.
- Neuroblastoma has been observed in a few FHS patients.
Observation:
- A case of melanotic neuroectodermal tumor of infancy (MNTI) in an infant with FHS was studied.
- Clinical, pathological, histochemical, and electron microscopic analyses were performed.
- This represents the first reported association of MNTI with FHS.
Findings:
- The case strengthens evidence for teratogenic and oncogenic effects of hydantoin compounds.
- Hydantoin exposure during gestation may increase the risk of certain childhood neoplasms.
- MNTI may be a manifestation of FHS.
Implications:
- Clinical vigilance for neoplasia in individuals with FHS is crucial.
- Detailed gestational drug histories are important for children diagnosed with neuroblastoma and other cancers.
- Further research is needed to confirm the definitive oncogenic effects of hydantoin compounds.
Abstract:
Fetal hydantoin syndrome (FHS), a characteristic pattern of altered growth and development, has been well described in recent years in offsprings of epileptic mothers taking phenytoin or other hydantoin anticonvulsants during the gestational period. Recent reports of neuroblastoma in three patients with the FHS further raise the questions of the "oncogenic effect " of hydantoin compounds. A case of melanotic neuroectodermal tumor of infancy (MNTI) has been studied clinically and pathologically including light microscopy, histochemistry, and electron microscopy. This case strengthens the evidence for the teratogenic and oncogenic effects of hydantoin compounds and we believe that it represents the first reported case of FHS associated with MNTI. It would be most important from a clinical standpoint to carefully scrutinize individuals with the FHS for neoplasias. Furthermore, detailed gestational drug history in children with neuroblastoma and other neoplasias should be carefully searched for, with the hope of clarifying the definitive oncogenic effect of hydantoin compounds.